Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | PFKFB3 | Q16875 | 7/20 | 0.55 |
| ▸ | CMA1 | P23946 | 7/20 | 0.55 |
| ▸ | PFKFB4 | Q16877 | 7/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6712744 | 0.98 | NPSR1 (0.59) | NPSR1L3MBTL1AKR1B1PFKFB3CMA1 | |
| SCHEMBL4658351 | 0.87 | NPSR1 (0.47) | NPSR1L3MBTL1AKR1B1PFKFB3CMA1 | |
| SCHEMBL337593 | 0.85 | NPSR1 (0.62) | NPSR1L3MBTL1AKR1B1PFKFB3CMA1 | |
| SCHEMBL1548591 | 0.85 | NPSR1 (0.62) | NPSR1L3MBTL1AKR1B1PFKFB3CMA1 | |
| SCHEMBL13696908 | 0.85 | NPSR1 (0.62) | NPSR1L3MBTL1AKR1B1PFKFB3CMA1 | |
| SCHEMBL3680145 | 0.81 | NPSR1 (0.69) | NPSR1L3MBTL1AKR1B1PFKFB3CMA1 | |
| SCHEMBL3956129 | 0.81 | NPSR1 (0.45) | NPSR1L3MBTL1AKR1B1PFKFB3CMA1 | |
| SCHEMBL3690124 | 0.81 | L3MBTL1 (0.45) | NPSR1L3MBTL1AKR1B1PFKFB3CMA1 | |
| SCHEMBL787942 | 0.81 | CMA1 (0.51) | NPSR1L3MBTL1AKR1B1PFKFB3CMA1 | |
| SCHEMBL3946161 | 0.81 | PFKFB3 (0.53) | NPSR1L3MBTL1AKR1B1PFKFB3CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | claimed |
| EP-2007729-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2012-06-27 | — | — | EP | claimed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | claimed |
| EP-1325920-B1 | N-SUBSTITUTED BENZOTHIOPHENESULFONAMIDE DERIVATIVES | TOA EIYO LTD (JP) | 2010-08-25 | — | — | EP | claimed |
| US-20100076036-A1 | HETEROCYCLYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | claimed |
| EP-2149573-A1 | Substituted indole sulfonamide compounds their preparation and use as medicaments | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | claimed |
| EP-2114929-A1 | HETEROCYCLYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | claimed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | claimed |
| EP-1248607-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-10-16 | — | — | EP | claimed |
| US-6423717-B1 | NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-23 | — | — | US | claimed |
| US-6380199-B1 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | SMITHKLINE BEECHAN P.L.C. (GB) | 2002-04-30 | — | — | US | claimed |
| WO-2001045694-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-28 | — | — | WO | claimed |
| EP-0853618-A4 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 2000-03-15 | — | — | EP | claimed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | claimed |
| US-5958918-A | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N- (aminominomethyl)phenylalkyl!-azaheterocyclylamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. | 1999-09-28 | — | — | US | claimed |
| EP-0853618-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-07-22 | — | — | EP | claimed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | claimed |
| WO-1996040679-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076036-A1 | HETEROCYCLYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | HTR6, HTR2A, HTR2C | NPSR1 25/4885L3MBTL1 3601/4885AKR1B1 2348/4885 |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | HTR6, HTR3B, HTR4 | NPSR1 88/4885L3MBTL1 2836/4885AKR1B1 2619/4885 |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | HTR6, HTR5A, HTR7 | NPSR1 156/4885L3MBTL1 4806/4885AKR1B1 1735/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | NPSR1 26/4885L3MBTL1 4613/4885AKR1B1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.